Home » Stocks » INM

InMed Pharmaceuticals, Inc. (INM)

Stock Price: $3.00 USD -0.38 (-11.24%)
Updated May 13, 2021 2:21 PM EDT - Market open
Market Cap 27.37M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 8.05M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.00
Previous Close $3.38
Change ($) -0.38
Change (%) -11.24%
Day's Open 3.25
Day's Range 3.00 - 3.40
Day's Volume 74,378
52-Week Range 2.65 - 6.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug ca...

1 week ago - GlobeNewsWire

VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceu...

1 week ago - GlobeNewsWire

VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a world leader in the clinical development of cannabinol (“CB...

2 weeks ago - GlobeNewsWire

All common shares will continue to be listed and tradable on the Nasdaq All common shares will continue to be listed and tradable on the Nasdaq

2 weeks ago - GlobeNewsWire

This yield level demonstrates commercial viability; supports advancing to large-scale production This yield level demonstrates commercial viability; supports advancing to large-scale production

2 weeks ago - GlobeNewsWire

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmac...

2 months ago - GlobeNewsWire

VANCOUVER, BC, Feb. 16, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseas...

2 months ago - PRNewsWire

VANCOUVER, BC, Feb. 11, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseas...

3 months ago - PRNewsWire

VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting disease...

3 months ago - PRNewsWire

InMed Pharmaceuticals Inc (NASDAQ: INM) has entered into definitive agreements with certain institutional investors to raise approximately $4.5 million at $4.25 per unit in a private placement. Each uni...

3 months ago - Benzinga

VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases ...

3 months ago - PRNewsWire

InMed's Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:...

3 months ago - PRNewsWire

TSX: IN NASDAQ: INM VANCOUVER, BC, Jan. 8, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medicatio...

4 months ago - PRNewsWire

VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting disease...

4 months ago - PRNewsWire

InMed Pharmaceuticals, a clinical stage biotech developing cannabinoid-based products, announced terms for its IPO on Thursday.

7 months ago - NASDAQ

About INM

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including d... [Read more...]

Industry
Biotechnology
CEO
Eric Adams
Country
Canada
Stock Exchange
NASDAQ
Ticker Symbol
INM
Full Company Profile

Financial Performance

Financial Statements